Veracyte Inc. (VCYT)
31.70
-0.53 (-1.64%)
At close: Apr 28, 2025, 3:59 PM
31.65
-0.16%
After-hours: Apr 28, 2025, 05:16 PM EDT
Veracyte Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Sep 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharmaceutical And Other Revenue | 3.14M | 3M | 18.92M | 4.56M | 6.13M | 6.8M | 7.7M | 10.04M | 8.82M | 11.16M | 6.51M | 2.69M | 3.06M | 2.7M | 2.03M | 1.71M | 5.06M | 90K | 90K | 90K | n/a |
| Biopharmaceutical And Other Revenue Growth | +4.39% | -84.12% | +314.75% | -25.63% | -9.75% | -11.74% | -23.28% | +13.76% | -20.96% | +71.38% | +142.34% | -12.13% | +13.46% | +33.00% | +18.33% | -66.13% | +5520.00% | 0.00% | 0.00% | n/a | n/a |
| Product Revenue | 3.19M | 3.54M | 15.59M | 4.01M | 3.89M | 3.23M | 3.31M | 3.11M | 2.98M | 16.37M | 2.96M | n/a | n/a | 31.5M | n/a | n/a | 37.56M | n/a | n/a | n/a | n/a |
| Product Revenue Growth | -9.87% | -77.31% | +288.63% | +3.06% | +20.46% | -2.50% | +6.63% | +4.33% | -81.80% | +453.09% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Testing Revenue | 109.54M | 90.3M | 326.54M | 81.75M | 72.4M | 70.27M | 64.58M | 59.72M | n/a | n/a | 16.07M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Testing Revenue Growth | +21.30% | -72.35% | +299.44% | +12.92% | +3.03% | +8.81% | +8.14% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|
| Non-Us Revenue | 33.61M | 18.53M | 7.87M |
| Non-Us Revenue Growth | +81.38% | +135.51% | n/a |
| United States Revenue | 262.92M | 200.98M | 109.61M |
| United States Revenue Growth | +30.82% | +83.35% | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 51.74M | 48.35M | 54.86M | 49.03M | 46.16M | 40.68M | 50.8M | 48.59M | 42.34M | 43.28M | 43.26M | 44.15M | 41.06M | 47.46M | 34.71M | 62.17M | 25.56M | 19.11M | 21.14M | 25.03M | 22.76M | 19.35M | 20.55M | 19.02M | 16.71M | 17.52M | 17.41M | 19.29M | 14.4M | 15.08M | 16.43M | 15.67M | 11.56M | 15.02M | 16.42M | 15.26M | 12.21M | 13.63M | 14.31M | 13.1M |
| Selling, General, and Administrative Revenue Growth | +7.00% | -11.86% | +11.90% | +6.20% | +13.49% | -19.93% | +4.55% | +14.78% | -2.18% | +0.03% | -2.00% | +7.52% | -13.49% | +36.74% | -44.17% | +143.22% | +33.76% | -9.62% | -15.53% | +9.95% | +17.65% | -5.82% | +8.01% | +13.82% | -4.64% | +0.65% | -9.75% | +33.96% | -4.49% | -8.23% | +4.84% | +35.61% | -23.06% | -8.50% | +7.56% | +25.02% | -10.40% | -4.77% | +9.25% | n/a |
| Research and Development Revenue | 19.29M | 17.57M | 16.22M | 15.73M | 18.41M | 13.32M | 12.54M | 12.77M | 11.29M | 10.77M | 9.38M | 9.17M | 10.25M | 2.2M | 6.25M | 5.34M | 4.59M | 4.04M | 1.26M | 4.41M | 4.44M | 3.64M | 3.33M | 3.44M | 3.13M | 1.18M | 2.21M | 1.06M | 3.2M | 847K | 1.36M | 1.71M | 3.59M | 1.83M | 2.19M | 1.49M | 3.34M | 1.71M | 1.27M | 1.11M |
| Research and Development Revenue Growth | +9.76% | +8.37% | +3.12% | -14.59% | +38.21% | +6.23% | -1.79% | +13.13% | +4.77% | +14.89% | +2.30% | -10.59% | +365.79% | -64.78% | +17.11% | +16.35% | +13.46% | +219.53% | -71.30% | -0.81% | +21.96% | +9.40% | -3.06% | +9.92% | +165.28% | -46.77% | +109.37% | -66.99% | +278.04% | -37.63% | -20.68% | -52.31% | +95.64% | -16.02% | +46.35% | -55.34% | +95.04% | +35.07% | +14.43% | n/a |
| Sales and Marketing Revenue | 24.82M | 22.61M | 7.13M | 6.16M | 7.1M | 24.34M | 25.76M | 26.13M | 24.13M | 25.68M | 6.74M | 4.97M | 22.21M | 21.67M | 19.66M | 3.43M | 13.15M | 10.96M | 2M | 17.58M | 14.18M | 13.09M | 13.94M | 12.48M | 10.07M | 10.08M | 9.62M | 11.54M | 9.04M | 7.88M | 7.99M | 7.34M | 5.83M | 7.09M | 8.26M | 7.07M | 6.69M | 6.05M | 6.94M | 5.62M |
| Sales and Marketing Revenue Growth | +9.78% | +216.92% | +15.83% | -13.26% | -70.83% | -5.48% | -1.43% | +8.30% | -6.04% | +280.98% | +35.59% | -77.62% | +2.50% | +10.21% | +473.74% | -73.94% | +20.03% | +446.66% | -88.60% | +23.98% | +8.37% | -6.13% | +11.75% | +23.95% | -0.15% | +4.76% | -16.63% | +27.62% | +14.71% | -1.36% | +8.97% | +25.79% | -17.71% | -14.23% | +16.94% | +5.67% | +10.57% | -12.82% | +23.43% | n/a |